Arbutus Biopharma Corp
ABUSHealthcare|Biotechnology|USA
$4.79
-0.34 (-6.52%)
Tangible Book
$1.32
Graham Number
$4.93
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06154278 Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B | Chronic Hepatitis B | P2 | Recruiting | 10 | Open-label | Imdusiran (AB-729) |
| NCT06277037 Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) | Long Term Follow-up | Recruiting | 50 | — | — | |
| NCT04980482 Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection | Chronic Hepatitis b | P2 | Completed | 43 | RCT, Open-label | AB-729, Peg-IFNα-2a |
| NCT04820686 A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection | Chronic Hepatitis B | P2 | Terminated | 65 | RCT, Open-label | VBR, AB-729, SOC NrtI |
| NCT02631096 Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy | Hepatitis B, Chronic | P2 | Completed | 36 | RCT, Single-blind | ARB-001467 |
| NCT01262235 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | Cancer, Neuroendocrine Tumors | P1P2 | Completed | 68 | Open-label | TKM-080301 |
| NCT06245291 Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection | Hepatitis B, Chronic | P2 | Withdrawn | — | RCT, Open-label | Imdusiran, Durvalumab |
| NCT02191878 Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma, Hepatoma | P1P2 | Completed | 43 | Open-label | TKM-080301 |
| NCT04775797 Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection | Chronic Hepatitis | P1 | Terminated | 110 | RCT, Double-blind | AB-836, Placebo, AB-836, Placebo, Nucleos(t)ide Analogue |
| NCT02041715 Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 | Ebola Virus Infection | P1 | Terminated | 21 | RCT, Single-blind | TKM-100802 for Injection, Placebo |
| NCT01518881 Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion | Ebola Virus Infection | P1 | Terminated | 24 | RCT, Single-blind | TKM-100201, Placebo |
| NCT00927459 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol | Hypercholesterolemia | P1 | Terminated | 23 | RCT, Single-blind | PRO-040201, Placebo |
| NCT05960240 Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects. | Chronic Hepatitis b | P1 | Completed | 128 | RCT, Single-blind | AB-101, Placebo, Nucleos(t)ide Analogue |